MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mardini, I. A.
Right arrow Articles by FitzGerald, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mardini, I. A.
Right arrow Articles by FitzGerald, G. A.
Molecular Interventions 1:30-38 (2001)
© 2001 American Society of Pharmacology and Experimental Therapeutics

Review

Selective Inhibitors of Cyclooxygenase-2

A Growing Class of Anti-Inflammatory Drugs

Issam A. Mardini,* and Garret A. FitzGerald

Center for Experimental Therapeutics and
* Department of Anesthesia University of Pennsylvania Philadelphia, USA

Correspondence: Address correspondence to GAF. E-mail garret{at}spirit.gcrc.upenn.edu; fax 215-573-9135.


For about two years, selective inhibitors of cyclooxygenase-2 have been hailed as powerful additions to the armamentarium of nonsteroidal anti-inflammatory drugs (NSAIDs). Predicted by financial analysts to become among the pharmaceutical industry's greatest-ever blockbusters, two so-called coxibs are now widely utilized clinically: rofecoxib (Vioxx, Merck) and celecoxib (Celebrex, Monsanto). The clinical advantages of the coxibs over traditional NSAIDs are related to the distinct roles played by cyclooxygenase-2 in comparison to its earlier described isoform, cyclooxygenase-1. Ongoing research into the disparate roles of the two isoforms will have implications not only for the pharmaceutical use of coxibs, but also for our basic appreciation of inflammation, cardiovascular diseases, Alzheimer's disease, cancer, and more.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. J. Welch, K. Patel, P. Modlinger, M. Mendonca, N. Kawada, K. Dennehy, S. Aslam, and C. S. Wilcox
Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2644 - H2649.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
R. Rajakariar, M. M. Yaqoob, and D. W. Gilroy
COX-2 in Inflammation and Resolution
Mol. Interv., August 1, 2006; 6(4): 199 - 207.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
K. Bachmann, D. White, L. Jauregui, J. I. Schwartz, N. G. B. Agrawal, R. Mazenko, P. J. Larson, and A. G. Porras
An Evaluation of the Dose-Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe
J. Clin. Pharmacol., October 1, 2003; 43(10): 1082 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
A. H. JESKE
Selecting new drugs for pain control: Evidence-based decisions or clinical impressions?
J Am Dent Assoc, August 1, 2002; 133(8): 1052 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. K. Hennan, J. Huang, T. D. Barrett, E. M. Driscoll, D. E. Willens, A. M. Park, L. J. Crofford, and B. R. Lucchesi
Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries
Circulation, August 14, 2001; 104(7): 820 - 825.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.